SCHEMBL2278135

SCHEMBL2278135

CC(C)C[C@H](NCCCCCOc1ccc(Br)cc1)C(=O)OC1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.53
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 2/20 0.50
NPR3 P17342 1/20 0.42
LSS P48449 3/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
ANPEP P15144 2/20 0.41
LTA4H P09960 1/20 0.41
LAP3 P28838 1/20 0.41
NPEPPS P55786 1/20 0.41
ERAP2 Q6P179 1/20 0.41
ERAP1 Q9NZ08 1/20 0.41
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
CACNA1B Q00975 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
RAB9A P51151 1/20 0.39
ADRB2 P07550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278139 1.00 MAPK14 (0.53) MAPK14KDM4EALDH1A1NPR3LSS
SCHEMBL2280784 0.96 MAPK14 (0.49) MAPK14KDM4EALDH1A1NPR3MMP2
SCHEMBL2280787 0.96 MAPK14 (0.49) MAPK14KDM4EALDH1A1NPR3MMP2
SCHEMBL3345286 0.85 MAPK14 (0.49) MAPK14KDM4EALDH1A1NPR3MMP2
SCHEMBL3345291 0.85 MAPK14 (0.49) MAPK14KDM4EALDH1A1NPR3MMP2
SCHEMBL3345202 0.84 MAPK14 (0.48) MAPK14KDM4EALDH1A1NPR3MMP2
SCHEMBL3345198 0.84 MAPK14 (0.48) MAPK14KDM4EALDH1A1NPR3MMP2
SCHEMBL2285961 0.83 MAPK14 (0.48) MAPK14KDM4ENPR3MMP2MMP9
SCHEMBL2285957 0.83 MAPK14 (0.48) MAPK14KDM4ENPR3MMP2MMP9
SCHEMBL2280856 0.82 MAPK14 (0.50) MAPK14NPR3MMP2MMP9ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078007-B1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-08-31 EP disclosed
US-8003695-B2 IKK-beta serine-threonine protein kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-08-23 US disclosed
US-20100087515-A1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS Chroma Terapeutics Ltd (GB) 2010-04-08 US disclosed
EP-2078007-A1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS Chroma Therapeutics Limited (GB) 2009-07-15 EP disclosed
WO-2008053182-A1 IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087515-A1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS IRAK3, IKBKE, IRAK1 MAPK14 654/4885KDM4E 2207/4885ALDH1A1 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.